477References
Alemi F, Zargoush M, Erdman H, et al. Genetic markers anticipate response to citalopram in a
majority of patients. Psychiatr Genet. 2011;21:287–93.
Arns M, Olbrich S. Personalized medicine in ADHD and depression: use of pharmaco-EEG. Curr
Top Behav Neurosci. 2014;21:345–70.
Batki SL, Pennington DL. Toward personalized medicine in the pharmacotherapy of alcohol use
disorder: targeting patient genes and patient goals. Am J Psychiatry. 2014;171:391–4.
Bierut LJ, Johnson EO, Saccone NL. A glimpse into the future – personalized medicine for smok-
ing cessation. Neuropharmacology. 2014;76 Pt B:592–9.
Breitenstein B, Scheuer S, Holsboer F. Are there meaningful biomarkers of treatment response for
depression. Drug Discov Today. 2014;19:539–61.
Caudill MM, Hunter AM, Cook IA, Leuchter A. The antidepressant treatment response index as a
predictor of reboxetine treatment outcome in major depressive disorder. Clin EEG Neurosci.
24 Sept 2014; pii: 1550059414532443.
Cross-Disorder Group of the Psychiatric Genomics Consortium; Genetic Risk Outcome of
Psychosis (GROUP) Consortium. Identifi cation of risk loci with shared effects on fi ve major
psychiatric disorders: a genome-wide analysis. Lancet. 2013;381:1371–9.
Dahl ML. Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful
aid to prescribing? Clin Pharmacokinet. 2002;41:453–70.
de Leon J, Susce MT, Pan RM, et al. The CYP2D6 poor metabolizer phenotype may be associated
with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry. 2005;66:15–27.
de Leon J, Sandson NB, Cozza KL. A preliminary attempt to personalize risperidone dosing using
drug-drug interactions and genetics: part I. Psychosomatics. 2008;49:258–70.
Holsboer F. How can we realize the promise of personalized antidepressant medicines? Nat Rev
Neurosci. 2008;9:638–46.
Hunter AM, Leuchter AF, Morgan ML, et al. Neurophysiologic correlates of side effects in normal
subjects randomized to venlafaxine or placebo. Neuropsychopharmacology. 2005;30:792–9.
Jang MH, Kitabatake Y, Kang E, et al. Secreted frizzled-related protein 3 (sFRP3) regulates anti-
depressant responses in mice and humans. Mol Psychiatry. 2013;18:957–8.
Johnson BA, Ait-Daoud N, Seneviratne C, et al. Pharmacogenetic approach at the serotonin trans-
porter gene as a method of reducing the severity of alcohol drinking. Am J Psychiatry.
2011;168:265–75.
Kiefer F, Witt SH, Frank J, et al. Involvement of the atrial natriuretic peptide transcription factor
GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate.
Pharmacogenomics J. 2011;11:368–74.
Kim SG, Kim CM, Choi SW, et al. A micro opioid receptor gene polymorphism (A118G) and nal-
trexone treatment response in adherent Korean alcohol-dependent patients. Psychopharmacology
(Berl). 2009;201:611–8.
Kranzler HR, Armeli S, Tennen H, et al. A double-blind, randomized trial of sertraline for alcohol
dependence: moderation by age of onset [corrected] and 5-hydroxytryptamine transporter-
linked promoter region genotype. J Clin Psychopharmacol. 2011;31:22–30.
Kranzler HR, Covault J, Feinn R, et al. Topiramate treatment for heavy drinkers: moderation by a
GRIK1 polymorphism. Am J Psychiatry. 2014;171:445–52.
McGorry P, Keshavan M, Goldstone S, et al. Biomarkers and clinical staging in psychiatry. World
Psychiatry. 2014;13:211–23.
Mutschler J, Abbruzzese E, Witt SH, et al. Functional polymorphism of the dopamine β-hydroxylase
gene is associated with increased risk of disulfi ram-induced adverse effects in alcohol-depen-
dent patients. J Clin Psychopharmacol. 2012;32:578–80.
Roiser JP, Cook LJ, Cooper JD, et al. Association of a functional polymorphism in the serotonin
transporter gene with abnormal emotional processing in ecstasy users. Am J Psychiatry.
2005;162:609–12.
References